美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Portola Pharmaceuticals Inc.

18.03

0.0000

成交量：- -

成交额：- -

市值：14.16亿

市盈率：-4.76

高：18.03

开：18.03

低：18.03

收：18.03

52周最高：31.73

52周最低：5.31

股本：7,851.73万

流通股本：7,322.61万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.7842

每股收益(LYR):-4.0621

净资产收益率：-462.25%

总资产收益率：-30.59%

市净率：19.65

市盈率(LYR):-4.44

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Portola Pharmaceuticals Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.portola.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Portola Pharmaceuticals, Inc.是一家生物制药企业。公司致力于在血栓疾病以及其他血液疾病和发炎病症领域研发新的疗法，同时将该疗法商业化。该疗法主要用于当前没有或认证疗法选择有限的病人。公司于2003年9月在特拉华州注册成立。公司总部以及业务范围在加利福尼亚州的南旧金山市，并以一个部门生产经营。公司两个主要项目用于解决血栓疾病和血凝块方面的问题。公司主要化合物是新型口服每日一次的贝曲西班，它是处于第三研发阶段凝血因子Xa的抑制剂，主要用于急性内科疾病患者静脉血栓栓塞的长期预防或预防性疗法。公司第二主要的候选研发药物是正处于概念取证阶段的PRT4445，它是一个主要用于逆转抗凝血生理活动的重组蛋白，该药主要用于使用抗凝血因子抑制剂治疗的患有不可控流血疾病或经历急诊外科手术的患者。公司第三种候选产品PRT2070是一种可口服的激酶抑制剂，该药物主要用于血液系统疾病、血液疾病、癌症及其他发炎类疾病。公司第四候选产品是 PRT2607，该药物由公司合作伙伴百健艾迪股份有限公司（Biogen Idec Inc.）开发研制，主要用于发炎类疾病。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PTLA/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","market":"US","secType":"STK","nameCN":"Portola Pharmaceuticals Inc.","latestPrice":18.03,"timestamp":1593633600000,"preClose":18.03,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":73226120,"shares":78517282,"eps":-3.784152,"marketStatus":"停牌","change":0,"latestTime":"07-01 16:00:00 EDT","open":18.03,"high":18.03,"low":18.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.784152,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1369195200000,"exchange":"NASDAQ","adjPreClose":18.03,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTLA\",,,,,undefined,":{"symbol":"PTLA","floatShares":73226120,"roa":"-30.59%","roe":"-462.25%","lyrEps":-4.062079,"shares":78517282,"dividePrice":0,"high":18.03,"amplitude":0,"preClose":18.03,"low":18.03,"week52Low":5.31,"pbRate":"19.65","week52High":31.73,"institutionHeld":0,"latestPrice":18.03,"eps":-3.784152,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.784152,"open":18.03,"prevYearClose":23.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-11","symbol":"PTLA","fiscalQuarterEnding":"2020/03","expectedEps":-0.74,"name":null,"time":"盘后","type":"earning","dateTimestamp":1589169600000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2020-02-26","symbol":"PTLA","fiscalQuarterEnding":"2019/12","expectedEps":-0.89,"name":null,"time":"盘后","type":"earning","dateTimestamp":1582693200000,"reportTimeType":"post","actualEps":-1.24},{"date":"2019-11-05","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.82,"defaultRemindTime":1572987600000,"name":null,"time":"盘后","dateTimestamp":1572930000000,"actualEps":null},{"date":"2019-08-07","symbol":"PTLA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-1.05,"defaultRemindTime":1565208000000,"name":null,"time":"盘后","dateTimestamp":1565150400000,"actualEps":-1.61},{"market":"US","date":"2019-05-08","symbol":"PTLA","fiscalQuarterEnding":"2019/03","expectedEps":-1.02,"name":null,"time":"盘前","type":"earning","dateTimestamp":1557288000000,"reportTimeType":"pre","actualEps":-1.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTLA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTLA","date":"2020-07-02","current":-4.764608,"percent":0.525692,"low":-8.397919,"twenty":-7.298314,"median":-5.390954,"eighty":-3.580615,"high":-1.552673,"avg":-5.298922,"sd":2.018062,"marketCap":1415666594},"quantilePoints":[],"updateTime":1774054917965},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.portola.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Portola Pharmaceuticals, Inc.是一家生物制药企业。公司致力于在血栓疾病以及其他血液疾病和发炎病症领域研发新的疗法，同时将该疗法商业化。该疗法主要用于当前没有或认证疗法选择有限的病人。公司于2003年9月在特拉华州注册成立。公司总部以及业务范围在加利福尼亚州的南旧金山市，并以一个部门生产经营。 公司两个主要项目用于解决血栓疾病和血凝块方面的问题。公司主要化合物是新型口服每日一次的贝曲西班，它是处于第三研发阶段凝血因子Xa的抑制剂，主要用于急性内科疾病患者静脉血栓栓塞的长期预防或预防性疗法。公司第二主要的候选研发药物是正处于概念取证阶段的PRT4445，它是一个主要用于逆转抗凝血生理活动的重组蛋白，该药主要用于使用抗凝血因子抑制剂治疗的患有不可控流血疾病或经历急诊外科手术的患者。公司第三种候选产品PRT2070是一种可口服的激酶抑制剂，该药物主要用于血液系统疾病、血液疾病、癌症及其他发炎类疾病。公司第四候选产品是 PRT2607，该药物由公司合作伙伴百健艾迪股份有限公司（Biogen Idec Inc.）开发研制，主要用于发炎类疾病。","exchange":"NASDAQ","name":"Portola Pharmaceuticals Inc.","nameEN":"Portola Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PTLA\",market:\"US\",,,undefined,":null}}